Detail akcie Valneva Sp ADS online

Business Summary: Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Valneva SE (ADR) revenues increased 38% to EUR97.6M. Net loss totaled EUR20.8M vs. income of EUR34M. Revenues reflect Product Sales increase of 33% to EUR91M, Other revenues increase from EUR2.5M to EUR6.5M. Net loss reflects Gain net de la vente du bon de revue pri decrease from EUR90.8M (income) to EUR0K, Research and development expenses increase of 9% to EUR32.4M (expense).